# Exenatide: new drug. Type 2 diabetes for some overweight patients.

> PubMed lists PMID 18087791 in Prescrire international as Journal Article, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-18087791-exenatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18087791-exenatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-18087791-exenatide-v1.json
- Content SHA-256: `38e3ae98884d8bac337dedf430f78728d7cac480cef4b21d0a495a2e5311c3ef`

## Claims and source pins

### Headline

Exenatide: new drug. Type 2 diabetes for some overweight patients. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

### Summary

PubMed lists PMID 18087791 in Prescrire international as Journal Article, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

### Paragraph 1

PubMed lists PMID 18087791 in Prescrire international as Journal Article, with publication-date metadata of 2007-12 (month precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`](#source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2))

## Sources

<a id="source-pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2"></a>
- **Exenatide: new drug. Type 2 diabetes for some overweight patients. · retained source version 1:2026-01-28:current:e3ed84d60ac24d613a41e78ba8cee2d1361360f65c1f3b4d7d95e1a6aa4d1300** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18087791/) (`pubmed-observation-pmid-18087791-2026-01-28-e3ed84d60ac2`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Exenatide: new drug. Type 2 diabetes for some overweight patients." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-18087791-exenatide-v1.json SHA-256: 38e3ae98884d8bac337dedf430f78728d7cac480cef4b21d0a495a2e5311c3ef.